Literature DB >> 20495568

Missing pieces in the Parkinson's disease puzzle.

Jose A Obeso1, Maria C Rodriguez-Oroz, Christopher G Goetz, Concepcion Marin, Jeffrey H Kordower, Manuel Rodriguez, Etienne C Hirsch, Matthew Farrer, Anthony H V Schapira, Glenda Halliday.   

Abstract

Parkinson's disease is a neurodegenerative process characterized by numerous motor and nonmotor clinical manifestations for which effective, mechanism-based treatments remain elusive. Here we discuss a series of critical issues that we think researchers need to address to stand a better chance of solving the different challenges posed by this pathology.

Entities:  

Mesh：

Year:  2010        PMID： 20495568     DOI： 10.1038/nm.2165

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  123 in total

Review 1.  Cognitive decline correlates with neuropathological stage in Parkinson's disease.

Authors:  Heiko Braak; Udo Rüb; Kelly Del Tredici
Journal:  J Neurol Sci       Date:  2006-06-30       Impact factor: 3.181

2.  Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.

Authors:  R Hilker; A V Thomas; J C Klein; S Weisenbach; E Kalbe; L Burghaus; A H Jacobs; K Herholz; W D Heiss
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

3.  Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.

Authors:  J H Kordower; T B Freeman; E Y Chen; E J Mufson; P R Sanberg; R A Hauser; B Snow; C W Olanow
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

4.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

5.  Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides.

Authors:  Martin Gluck; Julie Ehrhart; Elizabeth Jayatilleke; Gail D Zeevalk
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

6.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

Review 7.  The genetics of Parkinson's syndromes: a critical review.

Authors:  John Hardy; Patrick Lewis; Tamas Revesz; Andrew Lees; Coro Paisan-Ruiz
Journal:  Curr Opin Genet Dev       Date:  2009-05-04       Impact factor: 5.578

8.  Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

Authors:  Alexander Storch; Wolfgang H Jost; Peter Vieregge; Jörg Spiegel; Wolfgang Greulich; Joachim Durner; Thomas Müller; Andreas Kupsch; Henning Henningsen; Wolfgang H Oertel; Gerd Fuchs; Wilfried Kuhn; Petra Niklowitz; Rainer Koch; Birgit Herting; Heinz Reichmann
Journal:  Arch Neurol       Date:  2007-05-14

9.  A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals.

Authors:  Jonathan Moss; J Paul Bolam
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

10.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195
View more
  232 in total

1.  Natural toxins implicated in the development of Parkinson's disease.

Authors:  Mohamed Salama; Oscar Arias-Carrión
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Being too inclusive about synuclein inclusions.

Authors:  Ole Isacson; Ivar Mendez
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

4.  Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules.

Authors:  Ana Jorge-Finnigan; Rune Kleppe; Kunwar Jung-Kc; Ming Ying; Michael Marie; Ivan Rios-Mondragon; Michael F Salvatore; Jaakko Saraste; Aurora Martinez
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

5.  Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

Authors:  Xiomara A Pérez; Maryka Quik
Journal:  Mol Cell Pharmacol       Date:  2011

6.  Homocysteine and A2A-D2 Receptor-Receptor Interaction at Striatal Astrocyte Processes.

Authors:  Chiara Cervetto; Arianna Venturini; Diego Guidolin; Guido Maura; Mario Passalacqua; Carlo Tacchetti; Pietro Cortelli; Susanna Genedani; Simona Candiani; Paola Ramoino; Simone Pelassa; Manuela Marcoli; Luigi F Agnati
Journal:  J Mol Neurosci       Date:  2018-07-20       Impact factor: 3.444

Review 7.  Microtubule Destabilization Paves the Way to Parkinson's Disease.

Authors:  D Cartelli; G Cappelletti
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

8.  Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.

Authors:  Jun Kawamata; Syuuichirou Suzuki; Shun Shimohama
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

9.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

10.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

Authors:  J A Morales-García; C Susín; S Alonso-Gil; D I Pérez; V Palomo; C Pérez; S Conde; A Santos; C Gil; A Martínez; A Pérez-Castillo
Journal:  ACS Chem Neurosci       Date:  2012-12-05       Impact factor: 4.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.